BIORCHESTRA’s is a biotech firm that uses RNA-based therapies to identify new targets in neurodegenerative disorders. BIORCHESTRA’s has also created a unique nano-particle formulation to transport RNA-based medicines across the blood-brain barrier insufficient levels to be therapeutically efficacious in order to address these new targets.
Furthermore, their unique exosome-based diagnostic, which identifies and quantifies neuroinflammation and neurodegenerative indicators, aids in patient selection and therapy monitoring.Nonclinical models validate the significance of the BIORCHESTRA’s-targeted neuroinflammation and neurodegenerative pathways, as well as deep brain delivery of their patented medication, BMD-001, in rats and primates, as well as disease models of ALS and Alzheimer’s disease.
He is a better fit for BIORCHESTRA’s as he is expertise and experienced in every part of the drug development, regulatory affairs, , trial design and execution, and RNA. I’m thrilled to be working on a new medicine with such an outstanding specialist as Dr. O’Dea. Dr. O’Dea will be in charge of clinical operations, clinical research, clinical pharmacology, statistics, data management, and safety/pharmacovigilance for mRNA vaccines and neurodegenerative diseases.This will be an excellent chance for us to understand how outstanding biotechs like Moderna and Ionis (Akcea) have developed, overcome challenges, and generated products.